60NANB24D273
Project Grant
Overview
Grant Description
Purpose: This proposal requests funds for acquisition of a hot cell specifically designed for processing radioisotopes used in medical and other applications.
Specifically, a hot cell for production of Lutetium-177 (Lu-177) will be acquired.
Activities to be performed: The University of Missouri Research Reactor (MURR) operates 6.5 days/week throughout the year for routine, reliable production of radionuclides needed by various research, industrial, medical, defense, and other segments of the economy.
The overall goal of this project is to expand critical cancer-fighting research and medical isotope production, especially for Lutetium-177.
For this purpose, a hot cell for production of Lutetium-177 (Lu-177) will be acquired.
Expected outcomes: Lu-177 is the active pharmaceutical ingredient (API) manufactured by MURR used in breakthrough drugs to treat certain types of cancer.
MURR is presently the sole supplier of Lu-177 in North America.
Acquisition of the requested additional hot cell is a major initiative in maintaining supply for this isotope.
Intended beneficiaries: Lu-177 is now used in commercially available prescription cancer treatments, Lutathera and Pluvicto.
This product is used internationally in the diagnosis and treatment of prostate cancers.
With the promising characteristics of Lu-177 in cancer diagnosis and treatment, researchers are working worldwide to investigate the application of this isotope to other types of cancers.
This has resulted in a high demand for the isotope that is rapidly outpacing the current infrastructure for its production.
Increased production of Lu-177 will provide researchers and their students with the resources to explore nuclear science and discover new treatments that provide benefits to people around the country and the world.
Subrecipient activities: The recipient does not intend to subaward funds.
Specifically, a hot cell for production of Lutetium-177 (Lu-177) will be acquired.
Activities to be performed: The University of Missouri Research Reactor (MURR) operates 6.5 days/week throughout the year for routine, reliable production of radionuclides needed by various research, industrial, medical, defense, and other segments of the economy.
The overall goal of this project is to expand critical cancer-fighting research and medical isotope production, especially for Lutetium-177.
For this purpose, a hot cell for production of Lutetium-177 (Lu-177) will be acquired.
Expected outcomes: Lu-177 is the active pharmaceutical ingredient (API) manufactured by MURR used in breakthrough drugs to treat certain types of cancer.
MURR is presently the sole supplier of Lu-177 in North America.
Acquisition of the requested additional hot cell is a major initiative in maintaining supply for this isotope.
Intended beneficiaries: Lu-177 is now used in commercially available prescription cancer treatments, Lutathera and Pluvicto.
This product is used internationally in the diagnosis and treatment of prostate cancers.
With the promising characteristics of Lu-177 in cancer diagnosis and treatment, researchers are working worldwide to investigate the application of this isotope to other types of cancers.
This has resulted in a high demand for the isotope that is rapidly outpacing the current infrastructure for its production.
Increased production of Lu-177 will provide researchers and their students with the resources to explore nuclear science and discover new treatments that provide benefits to people around the country and the world.
Subrecipient activities: The recipient does not intend to subaward funds.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Columbia,
Missouri
65211-0001
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
University Of Missouri System was awarded
LU-177 Hot Cell Acquisition Grant for Cancer Research
Project Grant 60NANB24D273
worth $4,000,000
from the National Institute of Standards and Technology in September 2024 with work to be completed primarily in Columbia Missouri United States.
The grant
has a duration of 1 year 5 months and
was awarded through assistance program 11.617 Congressionally-Identified Projects.
Status
(Ongoing)
Last Modified 9/6/24
Period of Performance
9/1/24
Start Date
2/28/26
End Date
Funding Split
$4.0M
Federal Obligation
$0.0
Non-Federal Obligation
$4.0M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
60NANB24D273
SAI Number
60NANB24D273_0
Award ID URI
EXE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
1333ND DEPT OF COMMERCE NIST
Funding Office
1333ND DEPT OF COMMERCE NIST
Awardee UEI
SZPJL5ZRCLF4
Awardee CAGE
9C156
Performance District
MO-03
Senators
Joshua Hawley
Eric Schmitt
Eric Schmitt
Modified: 9/6/24